These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28400153)

  • 1. Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine.
    Roukos DH
    Drug Discov Today; 2017 Aug; 22(8):1148-1164. PubMed ID: 28400153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Med Res Rev; 2019 May; 39(3):1205-1227. PubMed ID: 30417574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine.
    Kyrochristos ID; Roukos DH
    Cancer Treat Rev; 2019 Nov; 80():101894. PubMed ID: 31518831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology.
    Ziogas DE; Kyrochristos ID; Roukos DH
    Expert Rev Med Devices; 2018 Jan; 15(1):1-3. PubMed ID: 29284319
    [No Abstract]   [Full Text] [Related]  

  • 5. Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies.
    Roukos DH
    Drug Discov Today; 2016 Apr; 21(4):663-73. PubMed ID: 26912452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology.
    Ziogas DE; Kyrochristos ID; Roukos DH
    Drug Discov Today; 2018 Nov; 23(11):1848-1872. PubMed ID: 30077778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementing Genome-Driven Oncology.
    Hyman DM; Taylor BS; Baselga J
    Cell; 2017 Feb; 168(4):584-599. PubMed ID: 28187282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
    Syn NL; Yong WP; Goh BC; Lee SC
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer.
    Angius A; Scanu AM; Arru C; Muroni MR; Carru C; Porcu A; Cossu-Rocca P; De Miglio MR
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.
    Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI
    OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
    Cheng F; Hong H; Yang S; Wei Y
    Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral heterogeneity and subclonal diversification of early breast cancer.
    Yates LR
    Breast; 2017 Aug; 34 Suppl 1():S36-S42. PubMed ID: 28666921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Drug Discov Today; 2019 Jun; 24(6):1281-1294. PubMed ID: 31009757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing in precision oncology: challenges and opportunities.
    Kruglyak KM; Lin E; Ong FS
    Expert Rev Mol Diagn; 2014 Jul; 14(6):635-7. PubMed ID: 24791810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proof-of-Concept Pilot Study on Comprehensive Spatiotemporal Intra-Patient Heterogeneity for Colorectal Cancer With Liver Metastasis.
    Kyrochristos ID; Glantzounis GK; Goussia A; Eliades A; Achilleos A; Tsangaras K; Hadjidemetriou I; Elpidorou M; Ioannides M; Koumbaris G; Mitsis M; Patsalis PC; Roukos D
    Front Oncol; 2022; 12():855463. PubMed ID: 35402285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering intratumor heterogeneity using cancer genome analysis.
    Ryu D; Joung JG; Kim NK; Kim KT; Park WY
    Hum Genet; 2016 Jun; 135(6):635-42. PubMed ID: 27126234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The new challenge in oncology: Next-generation sequencing and its application in precision medicine].
    Calabria I; Pedrola L; Berlanga P; Aparisi MJ; Sánchez-Izquierdo D; Cañete A; Cervera J; Millán JM; Castel V
    An Pediatr (Barc); 2016 Nov; 85(5):273.e1-273.e7. PubMed ID: 27349697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Genomic Era of Clinical Oncology: Integrated Genomic Analysis for Precision Cancer Care.
    Surrey LF; Luo M; Chang F; Li MM
    Cytogenet Genome Res; 2016; 150(3-4):162-175. PubMed ID: 28002823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.